Additionally, ezrin overexpression was associated with shortened 10-year survival for patients with early-stage cervical cancer (n=51, P=0.030), but this was not significant in patients with advanced-stage disease (data not shown, n=58, P=0.352), indicating that ezrin overexpression might be an effective biomarker for the prognostic evaluation of early-stage cervical cancer. The gene discussed is EZR; the disease is cervical carcinoma.